Literature DB >> 19759549

Loss of epidermal Langerhans cells occurs in human papillomavirus alpha, gamma, and mu but not beta genus infections.

Cheng Mee Leong1, John Doorbar, Ingo Nindl, Han-Seung Yoon, Merilyn H Hibma.   

Abstract

Human papillomaviruses (HPVs), which are contained in the alpha, beta, gamma, mu, and nu genera, differ in their oncogenic potential and their tropism for cutaneous or mucosal epidermis. Langerhans cells (LC), the only epidermal professional antigen-presenting cells, are readily detected in normal mucosal and cutaneous epithelium. The aim of this study is to determine whether LC loss, which has been reported for HPV16, occurs in other HPV genera and establish its significance in viral pathology. We found that, as for HPV16, LCs were reduced in lesions infected with high-risk mucosal (alpha7 and alpha9 species) and low-risk cutaneous (gamma and mu) types. Lesions infected with alpha10 low-risk genital types had reduced LC but contained epidermal LC patches, coincident with dermis-localized regulatory T cells (T-regs). In contrast to other genera, LCs were common in the epidermis, and T-regs occupied the dermis of the potentially high-risk cutaneous beta-HPV type infected lesions. Therefore, LC loss in the infected lesions occurred irrespective of tropism or oncogenic potential of the HPV type. LC depletion in the HPV-infected epidermis may create an environment that is permissive for viral persistence and in HPV lesions in which LCs are found, the presence of typically immunosuppressive T-regs may compensate for their continued presence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759549     DOI: 10.1038/jid.2009.266

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Absence of γ-Chain in Keratinocytes Alters Chemokine Secretion, Resulting in Reduced Immune Cell Recruitment.

Authors:  Karolin Nowak; Daniela Linzner; Adrian J Thrasher; Paul F Lambert; Wei-Li Di; Siobhan O Burns
Journal:  J Invest Dermatol       Date:  2017-06-17       Impact factor: 8.551

2.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

Review 3.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

4.  Moving forward with human papillomavirus immunotherapies.

Authors:  Nicolas Çuburu; John T Schiller
Journal:  Hum Vaccin Immunother       Date:  2016-07-07       Impact factor: 3.452

Review 5.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

6.  Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Joseph G Skeate; Laurie K Rijkee; Julia R Taylor; Heike E Brand; Laila I Muderspach; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Koji Matsuo; Yvonne G Lin; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Clin Immunol       Date:  2015-09-08       Impact factor: 3.969

Review 7.  Pathogenic Role of Immune Evasion and Integration of Human Papillomavirus in Oropharyngeal Cancer.

Authors:  Takashi Hatano; Daisuke Sano; Hideaki Takahashi; Nobuhiko Oridate
Journal:  Microorganisms       Date:  2021-04-21

8.  An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.

Authors:  Khairunadwa Jemon; Vivienne Young; Michelle Wilson; Sara McKee; Vernon Ward; Margaret Baird; Sarah Young; Merilyn Hibma
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

9.  Transcriptional repression of E-cadherin by human papillomavirus type 16 E6.

Authors:  Zarina J D'Costa; Carol Jolly; Elliot J Androphy; Andrew Mercer; Charles M Matthews; Merilyn H Hibma
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

10.  The immune response to papillomavirus during infection persistence and regression.

Authors:  Merilyn H Hibma
Journal:  Open Virol J       Date:  2012-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.